Literature DB >> 2833615

A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection.

S Jonjić1, M del Val, G M Keil, M J Reddehase, U H Koszinowski.   

Abstract

The nonstructural immediate-early protein pp89 of murine cytomegalovirus (MCMV) is the first viral protein synthesized after infection and has a regulatory function in viral gene expression. Despite its localization in the nucleus of infected cells, pp89 is also the dominant antigen recognized by MCMV-specific cytolytic T lymphocytes. The recombinant vaccinia virus MCMV-ieI-VAC, which expresses pp89, was used to study the capacity of this protein to induce protective immunity in BALB/c mice. Vaccination with MCMV-ieI-VAC induced a long-lasting immunity that protected mice against challenge with a lethal dose of MCMV but did not prevent infection and morbidity. In vivo depletion of CD8+ T lymphocytes before challenge completely abrogated the protective immunity. CD8+ T lymphocytes derived from MCMV-ieI-VAC-primed donors and adoptively transferred into sublethally irradiated and MCMV-infected recipients were found to limit viral replication in host tissues, whereas CD4+ T lymphocytes and pp89-specific antiserum had no protective effect. The data demonstrate for the first time that a single nonstructural viral protein can confer protection against a lethal cytolytic infection and that this immunity is entirely mediated by the CD8+ subpopulation of T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833615      PMCID: PMC253194          DOI: 10.1128/JVI.62.5.1653-1658.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives.

Authors:  J E Osborn
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

2.  Virulence characteristics of murine cytomegalovirus in cell and organ cultures.

Authors:  M C Jordan; J L Takagi
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

3.  Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.

Authors:  K L Rosenthal; J R Smiley; S South; D C Johnson
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

4.  Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes.

Authors:  U H Koszinowski; M J Reddehase; G M Keil; J Schickedanz
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

5.  Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein).

Authors:  S S Tevethia; D C Flyer; R Tjian
Journal:  Virology       Date:  1980-11       Impact factor: 3.616

6.  Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse.

Authors:  J E Chalmer; J S Mackenzie; N F Stanley
Journal:  J Gen Virol       Date:  1977-10       Impact factor: 3.891

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  Virulence and attenuation of murine cytomegalovirus.

Authors:  J E Osborn; D L Walker
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Molecular cloning and physical mapping of murine cytomegalovirus DNA.

Authors:  A Ebeling; G M Keil; E Knust; U H Koszinowski
Journal:  J Virol       Date:  1983-09       Impact factor: 5.103

10.  Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants.

Authors:  C R Bangham; P J Openshaw; L A Ball; A M King; G W Wertz; B A Askonas
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  50 in total

1.  Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus.

Authors:  H Hengel; U Reusch; G Geginat; R Holtappels; T Ruppert; E Hellebrand; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope.

Authors:  M Del Val; H J Schlicht; H Volkmer; M Messerle; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

Authors:  J van Zanten; M van der Giessen; L H van der Voort; W J van Son; W van der Bij; T H The
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge.

Authors:  J L Whitton; N Sheng; M B Oldstone; T A McKee
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

Review 6.  Recent progress in cytomegalovirus research.

Authors:  J D Benson; E S Huang
Journal:  Virus Genes       Date:  1990-02       Impact factor: 2.332

7.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

Authors:  L S Klavinskis; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo.

Authors:  Luka Cicin-Sain; Wolfram Brune; Ivan Bubic; Stipan Jonjic; Ulrich H Koszinowski
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.